0000899243-21-021552.txt : 20210602 0000899243-21-021552.hdr.sgml : 20210602 20210602162346 ACCESSION NUMBER: 0000899243-21-021552 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210602 DATE AS OF CHANGE: 20210602 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dunlop A. Sinclair CENTRAL INDEX KEY: 0001721108 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38276 FILM NUMBER: 21989438 MAIL ADDRESS: STREET 1: C/O APELLIS PHARMACEUTICALS, INC. STREET 2: 6400 WESTWIND WAY, SUITE A CITY: CRESTWOOD STATE: KY ZIP: 40014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001492422 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 271537290 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-977-5700 MAIL ADDRESS: STREET 1: 100 FIFTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-06-01 0 0001492422 Apellis Pharmaceuticals, Inc. APLS 0001721108 Dunlop A. Sinclair C/O APELLIS PHARMACEUTICALS, INC 100 FIFTH AVENUE WALTHAM MA 02451 1 0 0 0 Common Stock 2021-06-01 4 J 0 31855 0.00 D 0 I See Footnote Common Stock 2021-06-01 4 J 0 13108 0.00 A 73108 D Common Stock 2021-06-01 4 J 0 2682 0.00 A 303361 I See Footnote Distributions from MASA Life Science Ventures, LP ("MASA"), of which the reporting person is a managing partner. Of the 31,855 shares distributed by MASA, 13,108 were distributed to the reporting person and 2,682 were distributed to Epidarex Capital I, LP ("Epidarex"). The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein. The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein. /s/ David Watson, attorney-in-fact for A. Sinclair Dunlop 2021-06-02